Xenon Pharmaceuticals’ (XENE) “Outperform” Rating Reiterated at William Blair
William Blair restated their outperform rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) in a report published on Friday morning,RTT News reports. William Blair also issued estimates for Xenon Pharmaceuticals’ Q1 2026 earnings at $0.00 EPS, Q2 2026 earnings at ($1.01) EPS, Q3 2026 earnings at ($1.03) EPS and Q4 2026 earnings at […]
William Blair restated their outperform rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) in a report published on Friday morning,RTT News reports. William Blair also issued estimates for Xenon Pharmaceuticals’ Q1 2026 earnings at $0.00 EPS, Q2 2026 earnings at ($1.01) EPS, Q3 2026 earnings at ($1.03) EPS and Q4 2026 earnings at […]
